An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability

Journal of Pharmaceutical Sciences

Volumn 106, Issue 4, 2017, Pages 1008-1017

  Borrok, M Jack ^a   Mody, Neil ^a   Lu, Xiaojun ^a   Kuhn, Megan L ^a   Wu, Herren ^a   Dall'Acqua, William F ^a   Tsui, Ping ^a  

^a MEDIMMUNE   (United States)

Author keywords

benign blocker; biotechnology; CH2; calorimetry (DSC); developability; Fc silenced; IgG antibody; immunology; light scattering (dynamic); pharmacokinetics; protein aggregation; thermal analysis

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 TM; IMMUNOGLOBULIN G1 YTE; MACROGOL; UNCLASSIFIED DRUG; FC RECEPTOR IIA; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STABILITY; ELIMINATION HALF-LIFE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PLASMA CONCENTRATION-TIME CURVE; RAJI CELL LINE; RECEPTOR BINDING; SIZE EXCLUSION CHROMATOGRAPHY; STEADY STATE; SURFACE PLASMON RESONANCE; SURFACE PROPERTY; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; 129 MOUSE; ANIMAL; C57BL MOUSE; CHEMISTRY; GENE SILENCING; GENETICS; HALF LIFE TIME; HEK293 CELL LINE; HUMAN; MUTATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

ANIMALS; GENE SILENCING; HALF-LIFE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGG;

EID: 85011044824     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.12.023     Document Type: Article

References (56)

1. 1 Niwa, R., Hatanaka, S., Shoji-Hosaka, E., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 10:18 (2004), 6248–6255.
2. 2 Strohl, W., Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20:6 (2009), 685–691.
3. 3 Kaneko, E., Niwa, R., Optimizing therapeutic antibody function progress with Fc domain engineering. Biodrugs 25:1 (2011), 1–11.
4. 4 Pollreisz, A., Assinger, A., Hacker, S., et al. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro. Br J Dermatol 159:3 (2008), 578–584.
5. 5 Strohl, W.R., Strohl, L.M., Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry. 2012, Woodhead Publishing, Cambridge, UK.
6. 6 Bolt, S., Routledge, E., Lloyd, I., et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23:2 (1993), 403–411.
7. 7 Chao, D.T., Ma, X., Li, O., Park, H., Law, D., Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol Invest 38:1 (2009), 76–92.
8. 8 Idusogie, E.E., Presta, L.G., Gazzano-Santoro, H., et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164:8 (2000), 4178–4184.
9. 9 Shields, R.L., Namenuk, A.K., Hong, K., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:9 (2001), 6591–6604.
10. 10 Angal, S., King, D.J., Bodmer, M.W., et al. A single amino-acid substitution abolishes the heterogeneity of chimeric mouse/human (igG4) antibody. Mol Immunol 30:1 (1993), 105–108.
11. 11 Mueller, J.P., Giannoni, M.A., Hartman, S.L., et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol Immunol 34:6 (1997), 441–452.
12. 12 An, Z., Forrest, G., Moore, R., et al. IgG2m4, an engineered antibody isotype with reduced Fc function. mAbs 1:6 (2009), 572–579.
13. 13 Wines, B.D., Powell, M.S., Parren, P., Barnes, N., Hogarth, P.M., The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 164:10 (2000), 5313–5318.
14. 14 Vafa, O., Gilliland, G.L., Brezski, R.J., et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65:1 (2014), 114–126.
15. 15 Oganesyan, V., Gao, C., Shirinian, L., Wu, H., Dall'Acqua, W.F., Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 64 (2008), 700–704.
16. 16 Ward, E.S., Devanaboyina, S.C., Ober, R.J., Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 67:2 (2015), 131–141.
17. 17 Deng, R., Loyet, K.M., Lien, S., et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:4 (2010), 600–605.
18. 18 Hinton, P.R., Johlfs, M.G., Xiong, J.M., et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:8 (2004), 6213–6216.
19. 19 Yeung, Y.A., Leabman, M.K., Marvin, J.S., et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:12 (2009), 7663–7671.
20. 20 Zalevsky, J., Chamberlain, A.K., Horton, H.M., et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:2 (2010), 157–159.
21. 21 Borrok, M.J., Wu, Y.L., Beyaz, N., et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem 290:7 (2015), 4282–4290.
22. 22 Presta, L.G., Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:4 (2008), 460–470.
23. 23 Dall'Acqua, W.F., Kiener, P.A., Wu, H.R., Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:33 (2006), 23514–23524.
24. 24 Dall'Acqua, W.F., Woods, R.M., Ward, E.S., et al. Increasing the affinity of a human IgG1, for the neonatal Fc receptor: biological consequences. J Immunol 169:9 (2002), 5171–5180.
25. 25 Robbie, G.J., Criste, R., Dall'Acqua, W.F., et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrobial Agents Chemother 57:12 (2013), 6147–6153.
26. 26 Liu, Z., Gunasekaran, K., Wang, W., et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J Biol Chem 289:6 (2014), 3571–3590.
27. 27 Majumdar, R., Esfandiary, R., Bishop, S.M., et al. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. mAbs 7:1 (2015), 84–95.
28. 28 Ghirlando, R., Lund, J., Goodall, M., Jefferis, R., Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68:1 (1999), 47–52.
29. 29 Hristodorov, D., Fischer, R., Joerissen, H., Mueller-Tiemann, B., Apeler, H., Linden, L., Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol 53:3 (2013), 326–335.
30. 30 Tavakoli-Keshe, R., Phillips, J.J., Turner, R., Bracewell, D.G., Understanding the relationship between biotherapeutic protein stability and solid–liquid interfacial shear in constant region mutants of IgG1 and IgG4. J Pharm Sci 103:2 (2013), 437–444.
31. 31 Barnett, G.V., Qi, W., Amin, S., et al. Structural changes and aggregation mechanisms for anti-streptavidin IgG1 at elevated concentration. J Phys Chem B 119:49 (2015), 15150–15163.
32. 32 Thakkar, S.V., Sahni, N., Joshi, S.B., et al. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies. Protein Sci 22:10 (2013), 1295–1305.
33. 33 Ratanji, K.D., Derrick, J.P., Dearman, R.J., Kimber, I., Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol 11:2 (2014), 99–109.
34. 34 Hermeling, S., Schellekens, H., Maas, C., Gebbink, M., Crommelin, D.I.A., Jiskoot, W., Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95:5 (2006), 1084–1096.
35. 35 Shire, S.J., Shahrokh, Z., Liu, J., Challenges in the development of high protein concentration formulations. J Pharm Sci 93:6 (2004), 1390–1402.
36. 36 Edgeworth, M.J., Phillips, J.J., Lowe, D.C., Kippen, A.D., Higazi, D.R., Scrivens, J.H., Global and local conformation of human IgG antibody variants rationalizes loss of thermodynamic stability. Angew Chem Int Ed Engl 54:50 (2015), 15156–15159.
37. 37 Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S., Foeller, C., Sequences of Proteins of Immunological Interest. 5th ed., 1991, NIH, Bethesda, MD Publ. No91–3442.
38. 38 Goldberg, D.S., Bishop, S.M., Shah, A.U., Sathish, H.A., Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. J Pharm Sci 100:4 (2011), 1306–1315.
39. 39 Geoghegan, J.C., Diedrich, G., Lu, X., et al. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. mAbs 8:3 (2016), 454–467.
40. 40 Jayaraman, J., Wu, J., Brunelle, M.C., et al. Plasmonic measurements of monoclonal antibody self-association using self-interaction nanoparticle spectroscopy. Biotechnol Bioeng 111:8 (2014), 1513–1520.
41. 41 Gibson, T.J., McCarty, K., McFadyen, I.J., et al. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci 100:3 (2011), 1009–1021.
42. 42 Roopenian, D.C., Christianson, G.J., Sproule, T.J., et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170:7 (2003), 3528–3533.
43. 43 Tedder, T.F., Uchida, J., Hamaguchi, Y., Poe, J.C., CD-20 Specific Antibodies and Methods of Employing Same. 2009 United States Patent Application Publication US2009/0136516 A1.
44. 44 Hezareh, M., Hessell, A.J., Jensen, R.C., van de Winkel, J.G.J., Parren, P., Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 75:24 (2001), 12161–12168.
45. 45 Mimoto, F., Igawa, T., Kuramochi, T., et al. Novel asymmetrically engineered antibody Fc variant with superior Fc gamma R binding affinity and specificity compared with afucosylated Fc variant. mAbs 5:2 (2013), 229–236.
46. 46 Saluja, A., Fesinmeyer, R.M., Hogan, S., Brems, D.N., Gokarn, Y.R., Diffusion and sedimentation interaction parameters for measuring the second virial coefficient and their utility as predictors of protein aggregation. Biophys J 99:8 (2010), 2657–2665.
47. 47 Saito, S., Hasegawa, J., Kobayashi, N., Kishi, N., Uchiyama, S., Fukui, K., Behavior of monoclonal antibodies: relation between the second virial coefficient (B-2) at low concentrations and aggregation propensity and viscosity at high concentrations. Pharm Res 29:2 (2012), 397–410.
48. 48 Connolly, B.D., Petry, C., Yadav, S., et al. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J 103:1 (2012), 69–78.
49. 49 Nichols, P., Li, L., Kumar, S., et al. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. mAbs 7:1 (2015), 212–230.
50. 50 Li, L., Kantor, A., Warne, N., Application of a PEG precipitation method for solubility screening: a tool for developing high protein concentration formulations. Protein Sci 22:8 (2013), 1118–1123.
51. 51 Herbst, R., Wang, Y., Gallagher, S., et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 335:1 (2010), 213–222.
52. 52 Tam, S.H., McCarthy, S.G., Brosnan, K., Goldberg, K.M., Scallon, B.J., Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. mAbs 5:3 (2013), 397–405.
53. 53 Oganesyan, V., Damschroder, M.M., Leach, W., Wu, H., Dall'Acqua, W.F., Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 45:7 (2008), 1872–1882.
54. 54 Brader, M.L., Estey, T., Bai, S., et al. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm 12:4 (2015), 1005–1017.
55. 55 Cheng, W.Q., Joshi, S.B., He, F., et al. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. J Pharm Sci 101:5 (2012), 1701–1720.
56. 56 Nesspor, T.C., Raju, T.S., Chin, C.N., Vafa, O., Brezski, R.J., Avidity confers Fc gamma R binding and immune effector function to aglycosylated immunoglobulin G1. J Mol Recognit 25:3 (2012), 147–154.